Evidence map›Paper›PMID 40548968›Full record

ReviewDer Nervenarzt2026

[Genetically informed treatment in psychiatry: new dynamics through APOE and antibody treatment of Alzheimer's disease].

Daniel J Müller, Christine M Freitag, Urs Heilbronner, Markus M Nöthen, Robert Perneczky, Marcella Rietschel, Eva C Schulte, Jürgen Deckert, Referat Genetische, molekulare und zelluläre Neurowissenschaften der DGPPN

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pharmacogenetic analyses in people with dementia in Northeast Germany.Alzheimer's & dementia (Amsterdam, Netherlands)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel J MüllerOntario Shores Centre for Mental Health Sciences, Whitby, Ontario, and Department of Psychiatry, University of Toronto, 250 College Street, M5T 1R8, Toronto, Ontario, Kanada. daniel.mueller@camh.ca.
Christine M FreitagUniversitätsklinikum Frankfurt, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Goethe Universität, Frankfurt am Main, Deutschland.
Urs HeilbronnerInstitut für Psychiatrische Phänomik und Genomik (IPPG), LMU Klinikum, LMU München, München, Deutschland.
Markus M NöthenInstitut für Humangenetik, Universitätsklinikum Bonn, Bonn, Deutschland.
Robert PerneczkyKlinik und Poliklinik für Psychiatrie und Psychotherapie, LMU Klinikum, LMU München, München, Deutschland.
Marcella RietschelAbteilung Genetische Epidemiologie in der Psychiatrie, Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland.
Eva C SchulteInstitut für Psychiatrische Phänomik und Genomik (IPPG), LMU Klinikum, LMU München, München, Deutschland.
Jürgen DeckertKlinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Zentrum für Psychische Gesundheit, Universitätsklinikum Würzburg, Würzburg, Deutschland.
Referat Genetische, molekulare und zelluläre Neurowissenschaften der DGPPN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Medicines Agency has recommended testing for the ApoE-genotype prior to treatment of Alzheimer's disease with Lecanemab. The drug approval is limited to patients who are not homozygous for the ApoE epsilon 4 allele. This is to reduce the risk of undesired adverse effects in the patients treated with Lecanemab. With this recommendation for the first time a psychiatric therapy will be genetically informed.

Indexed as

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedApolipoproteins EGenetic TestingGenetic Predisposition to DiseaseHumansAntibodies, Monoclonal, HumanizedApolipoproteins EAdverse effectsAlzheimer diseaseApoE-genotypeLecanemabMedication safety

Identifiers

PMID40548968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.